Premier, Inc.’s PINC AI Applied Sciences and TFS HealthScience partner on AI-powered real-world data

Integrating AI technology and clinical development expertise, the collaboration between Premier, Inc.’s PINC AI Applied Sciences and TFS HealthScience aims to optimize recruitment, reach underrepresented populations, and expedite commercialization. Utilizing real-world data (RWD) and AI, the partnership focuses on inclusive, efficient clinical trial designs, reducing costs, and advancing global health equity.

In the collaboration, Premier, Inc.’s PINC AI™ Applied Sciences (PAS) and TFS HealthScience are partnering to revolutionize global clinical trials, advancing research innovation, improving patient outcomes, and addressing health disparities. This strategic integration combines PAS’ AI-enabled technology and extensive healthcare database with TFS’ clinical development capabilities, aiming to optimize global trial recruitment and operations, with emphasis on underrepresented populations, minimizing costs, and expediting the path to commercialization.

As a clinical research organization, TFS HealthScience will enhance trial site selection using comprehensive RWD and evidence (RWE) alongside AI tools from PAS. This data-driven strategy enables TFS to identify suitable sites based on key factors like patient populations, investigator availability, therapeutic areas expertise, and historical trial performance metrics. This is crucial given that 80% of all trials face premature termination or significant delays due to recruitment challenges; and, marginalized populations, including Black and Hispanic individuals, remain historically underrepresented. Notably, PAS-supported trials have already demonstrated success in improving recruitment rates by 1800% and tripling enrollment compared to initial projections. This transformative approach not only reduces enrollment periods and costs, but also addresses critical disparities in trial participation.

Denise Juliano, Group Vice President of Life Sciences at Premier, Inc., underscored the significance of the collaboration, stating, “The PAS–TFS partnership will bring the advantages of high-quality RWD/RWE and the benefits of AI-enabled technology to trial sponsors, investigators and life sciences entities worldwide.” The collaboration aims to advance global health equity by enhancing data analysis, promoting diverse and equitable trial designs, and supporting early disease detection.

Dr Bassem Saleh, CEO at TFS, envisions a global impact, stating, “Technology, including AI, will help accelerate clinical research through efficient clinical trial designs, synthetic arms and faster patient identification and recruitment. Working with PAS will open new avenues for innovative clinical trials in Europe and the US, benefiting biotech, pharma and medical device companies across various phases and RWE studies, and ensuring more inclusive and patient-centric research.” The partnership plans to implement data-driven designs across multiple studies yearly, integrating decentralized approaches with remote health options and in-home patient monitoring, lowering overall trial costs.

This strategic collaboration positions TFS for US expansion and enhances PINC AI’s global influence, especially in the European market. By consolidating capabilities, PAS and TFS are committed to advancing innovation in clinical research, offering efficient solutions that prioritize patient health outcomes and equity.